USFDA to authorize Pfizer, Merck COVID pills this week: Report
New Delhi: The U.S. Food and Drug Administration is set to authorize COVID-19 treatment pills from both Pfizer Inc and Merck as early as December 22, Bloomberg News reported on Tuesday, citing people familiar with the matter.
The two drugs, especially Pfizer's pill Paxlovid, are seen as promising new oral treatments that can be taken upon onset of symptoms at home to help prevent COVID-19 hospitalizations and deaths.
Merck's drug, molnupiravir, developed with Ridgeback Biotherapeutics, was shown to reduce hospitalizations and deaths by around 30% in a clinical trial of high-risk individuals early in the course of the illness.
Molnupiravir gained a narrow vote in favor of authorization by a panel of advisers to the FDA on Nov. 30.
Meanwhile, Pfizer's Paxlovid showed near 90% efficacy in preventing hospitalizations and deaths in high-risk patients.
Britain in November became the first country in the world to approve Merck's antiviral drug for use in people with mild to moderate COVID-19 and for those who have at least one risk factor for developing severe illness.
The United States has a contract to buy as many as 5 million courses of Merck's drug, and 10 million courses of Pfizer's treatment.
Read also: EU drug agency gives advice on use of Pfizer Covid-19 pill
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.